Ambio participated closely in the design and data collection for a standardized research tool designed to measure ibogaine’s subjective effects. Existing research instruments didn’t capture the unique subjective qualities of ibogaine, and so this measure was developed for inclusion in future research studies.
The groundbreaking study “Stanford Study” looked at 30 retired Navy SEALs with traumatic brain injury who demonstrated major improvement across a variety of psychometric symptoms, including disability, post-traumatic stress, depression and anxiety. This paper helped to spark a major upsurge in ibogaine research and even state-level funding initiatives in the US.
Ambio published this preliminary case report on two patients with various stages of multiple sclerosis (MS): a man with relapsing remitting MS, and a woman with secondary progressive MS. We demonstrated broad symptomatic improvement that occurred alongside structural changes in the brain. The male RRMS case showed a 71% reduction in the volume of white matter lesions post-treatment.
Ambio published this unique case involving a single patient with severe, intractable neuropathic pain 20 years after a motorcycle accident. We demonstrate the development of a customized pain-treatment protocol that showed robust analgesic effects with enduring improvements, suggesting a restorative neurological benefit.
Listen to our 2-year follow-up with the patient on the Ambio Podcast episode 7 (YouTube / Spotify).
In this paper, Ambio’s CEO, Jonathan Dickinson, demonstrated how close examination of raw experiential reports easily reveals often-ignored phenomenology in the ibogaine experience. Specifically, he described an “intersubjective” effect of communication with an other, which corresponds to numerous anthropological descriptions from other hypnagogic or hypnopompic dream states, particularly cases of sleep paralysis.
Jonathan Dickinson, Ambio’s CEO, collaborated with researchers at the Universidad Autonoma de Mexico to evaluate the iboga-alkaloid content of Mexican tree species from the Apocynacae family.
Trevor Millar, Ambio’s COO, participated in an early case report with researchers from the University of British Columbia, describing the successful reduction of opioid withdrawal in a single patient who had been addicted to heroin for over 18 years.
In his previous role as the Executive Director of the Global Ibogaine Therapy Alliance, Jonathan Dickinson, now Ambio’s CEO, led the development of a clinical guideline document that set the standard for mitigating cardiac and drug interaction risks with ibogaine. The protocols described in this document are the scaffolding for safety measures used by Ambio and other ibogaine clinics worldwide.
In this invited review article, Ambio’s CEO, Jonathan Dickinson, provides a foundational outline for iboga and ibogaine’s use in the Western world and early evaluations of its impact on traditional knowledge holders in Gabon.
This follow-up paper on the Stanford Study describes some of the changes that researchers observed with advanced neuroimaging. They describe fluctuations in electrical activity pre- and post-treatment that correlate with increases in cognitive clarity and other psychometric improvements.
This paper analyzed participants in the Stanford Study (listed above), and showed corresponding improvements in the quality of sleep, alongside other psychometric improvements.
A survey of US veterans who received ibogaine and 5-MeO-DMT, conducted by Ohio State University, showed large reductions in suicidal ideation, cognitive impairment, and negative mental health symptoms. A vast majority of participants rated the experience amongst the most personally and spiritually meaningful experiences of their lives.
One of the first brain imaging studies on a human patient. A US military veteran received ibogaine and 5-MeO-DMT, and showed increased brain profusion in relevant brain regions, corresponding with a reduction in alcohol use and an increase in mood.
For a full description of these studies, see our blog post: What Are Ibogaine’s Success Rates in Addiction Treatment?
A survey of US veterans who received ibogaine and 5-MeO-DMT, conducted by Ohio State University, showed large reductions in suicidal ideation, cognitive impairment, and negative mental health symptoms. A vast majority of participants rated the experience amongst the most personally and spiritually meaningful experiences of their lives.
One of the first brain imaging studies on a human patient. A US military veteran received ibogaine and 5-MeO-DMT, and showed increased brain profusion in relevant brain regions, corresponding with a reduction in alcohol use and an increase in mood.
Thomas Kingsley Brown of UCSD provides a strong high-level review of the science behind ibogaine’s use as an anti-addiction therapy.
This MAPS-funded study tracked 30 patients after opioid detox at a clinic in Mexico for 1 year. They found that 30 days after treatment, 50% of the patients remained completely abstinent from opioids. After 1 year, 40% of subjects were defined as having a “favorable outcome,” meaning that they stayed in touch with the study team for at least 9 months, and reported at least a 75% reduction in Addiction Severity Index (ASI) Drug Use scores.
This MAPS-funded study followed 14 patients after opioid detox at a clinic in New Zealand for 1 year. 50% of their patients reported abstinence 1 year after treatment, as well as other positive psychological outcomes.
This study from Ohio State University retroactively reached out to 88 patients who went to a clinic in Mexico. At various stages post-treatment (mostly 1-2 years later), these patients said that ibogaine had reduced withdrawal (80% of cases), reduced opioid cravings (50% of responses), and helped them to maintain abstinence for at least 6 months (41%). 30% reported never using opioids again.
This Brazilian study look followed 75 patients who were treated for a variety of addictions (mostly cocaine paste). They showed 61% remained abstinent, although these rates increased following multiple (up to 4) treatments.
The study involved 30 former Navy SEALs who received ibogaine treatment at Ambio’s clinics in Mexico to address traumatic brain injuries sustained during their military service.
Our patent filings have all been executed using the context of the Nagoya-protocol on access and benefits sharing, with prior and informed consent of traditional knowledge holders in Gabon.
Ambio provided the first published discovery on the use of ibogaine to treat multiple sclerosis, showing a robust improvement across motor and psychological symptoms in two patients.
Ambio developed the use of cardiac prophylaxis and metabolic support into a novel, standardized cotherapy protocol.
Ambio provided the first published discovery on the use of ibogaine to treat post-stroke symptoms in a variety of patients.
Our patent filings have all been executed using the context of the Nagoya-protocol on access and benefits sharing, with prior and informed consent of traditional knowledge holders in Gabon.
